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1. Introduction
Sickle cell disease (SCD) is the commonest inherited 
haemoglobin disorder, with approximately 70 million 
affected individuals worldwide. The highest gene 
frequencies are encountered in tropical regions, 
particularly equatorial Africa, the Arabian peninsula, India, the 
Mediterranean, the Caribbean and South America. The protective 
effect of the heterozygous state against malaria has led to persistence 
of the sickle gene in malarial endemic areas.
South Africa (SA) is not a malarial endemic area, and so has a 
predictably low prevalence of SCD (<1%). However, with relaxed 
border controls since 1994, the influx of people from other African 
states has been accompanied by an influx of the sickle gene. Clinicians 
are therefore encountering an increasing number of patients with the 
disease.
Under conditions of decreased oxygen tension, HbS polymerises 
linearly in an alpha-helical fashion to form ‘tactoids’ that force 
red cells to elongate at two opposite ends and eventually assume a 
sickle shape (or variants thereof). Upon re-entry to the pulmonary 
circulation and subsequent reoxygenation of HbS, sickle cells 
revert to their original shape. Repeated cycles of sickling and 
unsickling cause membrane damage and increased rigidity, which 
ultimately leads to formation of irreversibly sickled cells. Normal 
biconcave red cells are pliable and can easily squeeze through the 
microcirculation, but owing to their elongated shape, sickle cells 
are not as flexible. In addition, sickle cells have exposed receptors 
that bind to integrins on the endothelial surface, which makes them 
‘sticky’. In the presence of predisposing factors, e.g. infec tion, 
sickle cells therefore get trapped in the microcirculation and 
cause obstruction to flow, with resulting ischaemia. The severe pain 
that may be experienced at the site of ischaemia, commonly referred 
to as an ‘acute pain crisis’ or ‘acute sickle crisis’, is a hallmark of the 
disease. Chronic organ damage results from repeated infarctive 
episodes.
The only intervention that may be curative is stem cell trans-
plantation (SCT), but this comes at considerable cost and requires 
expertise (Appendix 4). Gene therapy is experimental and if successful 
would overcome some of the hurdles of SCT.
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2. Acute crises
2.1 Acute vaso-occlusive crisis (VOC) (synonyms:  
acute pain crisis, acute sickle crisis)[1]
Acute VOC is the hallmark of SCD, and is the most common acute 
presentation. Long bones are the most common sites for acute VOC, 
but any other site or organ may be involved, including the axial skeleton, 
abdomen, chest, kidneys, central nervous system and soft tissues.
In infants and young children, acute VOC involving small bones of 
the hands and feet (dactylitis), typically occurring between the ages 
of 6 months and 3 years, may be the first presenting manifestation of 
SCD. This causes acute pain as well as swelling and tenderness of the 
affected regions, often dubbed the ‘hand-foot syndrome’.
Any drop in oxygen tension or related events can precipitate a 
sickle crisis. Precipitating factors include:
A.  Acidosis, anaesthesia, anxiety, (high) altitude
B.  Bouts of infection, bad habits, e.g. smoking, alcohol
C.  Cold exposure
D.  Dehydration
E.  Exercise (vigorous)
F.  Folate deficiency (e.g. megaloblastic crisis)
G.  General surgery
H.  Hypoxia
I.  Infection
O.  Other – trauma, menstruation.
Fever frequently accompanies a pain crisis. As the temperature rarely 
exceeds 38oC, temperatures above this level should be investigated, guided 
by the clinical findings and further investigations, e.g. chest radiograph, 
and blood/urine culture. Empiric antibiotics should be administered until 
culture results are known, and adjusted where necessary.
Acute VOC often causes excruciating pain and can lead to despair 
and panic. Pain is experienced as a result of tissue ischaemia that 
results from sludging or occlusion of the microcirculation by sickled 
red cells. Vaso-occlusion of cerebral vessels results in clinical stroke 
or silent cerebral infarcts.
• Vigorous hydration with intravenous fluids (normal saline or 5%
dextrose in saline) is necessary.
• Check oxygen saturation and administer oxygen if <95%.
2.1.1 Acute pain
Pain management should be individualised, as patients have varying 
thresholds of pain and different levels of tolerance from past exposure 
to analgesics.
Management:
• Prehospital care: bed rest, hydration and simple oral analgesia
should be instituted by the patient. Failure of self-treatment should 
mandate prompt referral to hospital (emergency department/
casualty/admission ward).
• Upon admission, rapid clinical assessment and reassurance are
important.
• Analgesics should be administered as soon as possible, and within
30 minutes of arrival at hospital.
• For mild to moderate pain, paracetamol with codeine, non-
steroidal anti-inflammatory drugs (NSAIDs) or tramadol (tilidine
in the case of children) may be used as single agents or in
combination, bearing in mind the World Health Organization
(WHO) three-step ladder for pain management:
• Step 1: Mild pain – non-opioid ± adjuvant
• Step 2: Moderate pain – weak opioid (or low dose of strong
opioid) ± non-opioid ± adjuvant
• Step 3: Severe pain – strong opioid ± non-opioid ± adjuvant).
• Opioids are generally required for severe pain. Morphine is
the drug of choice, except where contraindicated (e.g. allergy,
intracranial disease, liver disease, etc.). Ideally morphine should
be administered parenterally at fixed intervals. Table 1 serves as a
general guide to dosing.
Close monitoring of vital signs, pain control and sedation is 
essential at 15 - 20-minute intervals for the first hour, then at 
30-minute intervals, and thereafter 2-hourly once pain control 
has been achieved. After 24 - 48 hours of pain relief, parenteral 
morphine should be weaned off over the next 2 - 3 days. A non-
opioid analgesic, such as paracetamol or an NSAID, may be added 
as an adjunct. For breakthrough pain, oral morphine solution 
can be used (e.g. 5 - 10 mL 4 - 6-hourly). The frequency of and 
response to pain-relieving medication should be documented with 
pain charts or scales appropriate to the patient’s age and cognitive 
abilities. Patient-controlled analgesia pumps are particularly useful 
for frequent, ongoing pain and should be offered where available. 
For morphine-related side-effects and their management, see 
Table 1.
Routine use of sedatives should be avoided. For extremely anxious 
and agitated patients, anxiolytics such as haloperidol, benzodiazepines 
or antihistamines may be used with caution. 
Chronic pain is discussed under complications and organ damage (3.8).
2.1.2 Stroke[2,3]
The incidence of stroke is highest between 2 and 11 years of age, with 
up to 30% of individuals being affected (the SA experience however, 
seems to suggest a lower incidence).
• Haemorrhagic stroke. Adults with SCD and moya-moya are at
risk of recurrent intracranial haemorrhage. Bleeding aneurysms
have been successfully treated with interventional neuroradiology
(embolisation with coils) or surgery (craniotomy and clipping).
• Arterial stroke. In the acute phase, SCD patients with arterial
stroke should undergo exchange transfusion, with the aim of
achieving an HbS percentage <30%. As there is a high prevalence
of a second stroke, it is recommended that these patients be put
onto a chronic transfusion regimen, either top up or exchange
transfusion (see below). There is no clear guidance on when to
stop the transfusions.
• Primary stroke prevention. Long-term red cell transfusion is
the mainstay of stroke prevention in SCD. It is possible to
identify patients at high risk for developing stroke. Cerebral vessel
velocities, as measured by transcranial Doppler (TCD) imaging,
exceeding 200 cm/s increase the risk (high risk) for developing
stroke. The predictive value of TCD velocity is limited to children,
as the velocity rarely exceeds 200 cm/s in adults.
• Secondary stroke prevention. Following a first ischaemic stroke,
the risk of recurrence in untreated cases is 50 - 92%. This risk
is reduced to about 10% by regular transfusions to maintain an
HbS level <30%. The initial transfusion should be an exchange
transfusion and may be followed by simple transfusions. Chronic
transfusion is superior to hydroxyurea in stroke prevention.
• Covert infarction. The incidence of silent cerebral infarcts
is 7.06/100 patient-years. There should be a high index of
suspi cion when patients present with cognitive abnormalities.
Detection of cerebral infarcts is possible on magnetic resonance 
imaging (MRI).
• Epilepsy. There is a ten-fold increase in the occurrence of
seizures in SCD compared with the general population. These are
associated with silent infarcts and overt cerebrovascular disease.
Seizures should be managed with anticonvulsants.
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2.1.3 Acute chest syndrome (ACS)[4]
ACS is the leading cause of death in SCD, and is characterised by:
• Fever – temperature >38.5oC
• Respiratory symptoms and signs, including cough, chest pain,
dyspnoea or wheezing
• A new pulmonary infiltrate on chest X-ray (e.g. consolidation,
segmental changes, etc.)
• ACS may begin as a pain crisis affecting the ribs, chest or
shoulders. The pathogenesis involves vaso-occlusion, fat embolism 
and pulmonary thromboembolism. There is also a bronchoreactive 
component. Complications of an ACS include respiratory failure,
central nervous system injury (from anoxia, infarction or
haemorrhage), seizures, non-cardiogenic pulmonary oedema and
multiorgan failure (from hypoxia, resulting in widespread sickling
and VOC). Patients with ACS are best cared for in a high-care
facility.
Management of ACS:
• Bed rest, hydration and analgesia
• Oxygen supplementation – oxygen may be administered to
moderately hypoxaemic patients (arterial oxygen tension 70 - 80
mmHg; oxygen saturation 92 - 95%) nasally at a rate of 2 L/min
• Antibiotics are indicated as infection is a common precipitant of
ACS, and should include a macrolide (e.g. erythromycin) to cover
atypical organisms, combined with a second- or third-generation
cephalosporin. The choice of antibiotics may be modified based on 
the age of the patient and the institutional sensitivity and resistance 
patterns.
• Bronchodilators should be prescribed for patients with evidence
of bronchospasm.
• Blood transfusion. Where there is severe anaemia or significant
drop in haemoglobin concentration (≥2 g/dL), a blood transfusion 
is required. An exchange transfusion is indicated if there is
evidence of hypoxia (±5 - 10% drop from the baseline oxygen
saturation level or paO2 <70 mmHg) and in deteriorating patients,
since acute respiratory failure can supervene rapidly. Exchange 
transfusion in this setting often results in dramatic improvement.
• For severe hypoxia (paO2 <60 mmHg), continuous positive airways 
pressure (CPAP) and mechanical ventilation may be necessary.
• Incentive spirometry is useful in preventing complications such as
atelectasis and pulmonary infiltrates in patients experiencing pain 
above the diaphragm.
2.1.4 Abdominal crisis
An abdominal crisis most commonly arises from occlusion or 
infarc tion of mesenteric vessels and can mimic an acute abdomen, 
e.g. intestinal obstruction, cholecystitis, acute appendicitis or 
pancreatitis. Bowel ischaemia often causes abdominal pain that has 
a girdle distribution, called the ‘girdle syndrome’. Ischaemic colitis 
causes thickening of the intestinal wall that can be detected on an 
abdominal computed tomography scan. Angiography does not image 
smaller vessels reliably and has limited diagnostic value.
Conservative management with rehydration and analgesia 
generally leads to resolution within 2 - 4 days. Colonoscopy is 
indicated if infarction is suspected. Progression to severe ischaemic 
colitis necessitating colonic resection is rare and can be avoided 
by optimising colonic perfusion with exchange blood transfusion, 
intravenous broad-spectrum antibiotics and several days of bowel 
rest. However, there is a risk of bowel perforation if there is no 
response within 2 weeks. Patients who develop peritonitis, sepsis or 
gangrene (identified through endoscopy) or whose clinical condition 
deteriorates despite conservative management should undergo 
laparotomy for resection of the affected bowel segment.
2.1.5 Priapism[5,6]
Priapism is an unwanted, persistent, painful erection of the penis. 
By the age of 20 years, 30 - 45% of men with SCD will have suffered 
at least one episode of priapism. It can occur as an acute sustained 
attack or as recurrent shorter episodes (stuttering). If an episode 
lasts more than 3 - 4 hours, it can lead to erectile dysfunction. It is 
Table 1. Suggested dosing of morphine for pain in SCD and management of side-effects
Morphine Adult Paediatric
Suggested dosing Initial dose (administered until 
pain control achieved)
0.1 mg/kg IV every 15 - 30 min OR
10 μg/kg/h as a continuous IV 
infusion 
0.1 - 0.15 mg/kg (max 7.5 mg/dose)
Repeat morphine once after 60 min if 
inadequate pain relief
Subsequent dosing after pain 
control achieved
0.05 - 0.1 mg/kg IV every 2 - 4 hours Additional IV boluses of morphine can 
be given – 0.05 mg/kg 1 - 2-hourly as 
required
If unable to obtain venous 
access
Initial dose: 0.1 mg/kg SC followed by 
0.05 - 0.1 mg/kg SC 2 - 4-hourly
0.1 - 0.2 mg/kg SC 4-hourly
Side-effects Constipation Lactulose 10 mL bid OR
Senna 2 - 4 tablets daily
Lactulose 5 mL bid
Senna 1 - 2 tabs daily (>6 yr)
Nausea and vomiting Prochlorperazine 5 - 10 mg tds OR
Cycline 50 mg tds
Prochlorperazine 7.5 mg daily oral/
rectal
Pruritus Hydroxyzine 25 mg bid OR
Cetrizine 10 mg nocte OR
Promethazine 25 mg tds
Hydroxyzine 5 - 15 mg/day (<6 yr)
Cetrizine 5 mg/d
Promethazine 5 - 15 mg/day (CI <2 yr)
Respiratory depression Stop opioid analgesics 
Naloxone 0.4 - 2 mg IV
Repeat when necessary
Stop opioid analgesic
Naloxone 0.01 mg/kg IV
Repeat with 0.1 mg/kg when necessary
SCD = sickle cell disease; IV = intravenous; SC = subcutaneous; bid = 12-hourly; tds = 8-hourly; CI= contraindicated. 
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important for patients to be educated to abort attacks of priapism. 
Newer management ensures that more than 70% of men with SCD 
remain potent.
Management principles of priapism include:
• Simple measures: urination, hydration, hot baths, adequate
analgesia (including morphine for severe pain in hospitalised
patients – see management of acute pain above). Do not apply ice,
as this will slow the circulation.
• Aspiration and irrigation of the corpora cavernosa.
• Intracavernous injection of sympathomimetic agents, such as
phenylephrine (add 1 mL of a 10 mg/mL solution to 500 mL of 0.9% 
saline; administer 1 mL of the solution every 3 - 5 minutes for up to
an hour, before proceeding to the next step), or as a second option
epinephrine (add 1 mL of a 1:1 000 solution to 1 000 mL saline).
• Surgical shunting (performed by a urologist) would be indicated
for ongoing, refractory ischaemic priapism.
• Once the acute episode has settled, review and optimise the
comprehensive care of the patient.
• If stuttering priapism persists despite optimal treatment, specific
prophylaxis and home treatment should be considered. This
includes oral pseudoephedrine (30 mg at night if <10 years of age;
60 mg at night if >10 years) or oral etilefrine (25 mg at night for
adults).
• A urologist and a clinical psychologist should be involved in the
management of patients who develop erectile dysfunction. There
are various medical and prosthetic options available for such
patients.
2.2 Splenic sequestration crisis
This is a life-threatening emergency where the spleen enlarges very 
rapidly, sometimes within hours, and causes massive pooling of 
blood. The effect is synonymous with internal exsanguination with 
development of acute anaemia.
Splenic sequestration is most common in early childhood but may 
be encountered in older children and adults, particularly those with 
compound heterozygous sickle-β thalassaemia or HbSC disease.
Early and urgent blood transfusion is life-saving. Splenectomy is 
generally indicated for recurrent life-threatening episodes (usually 
after 4 - 6 years of age).
When the spleen regresses to its original size, the blood returns to 
the main circulation, which may increase the haemoglobin to above 
baseline levels. This is known as reverse sequestration and poses a 
risk for developing acute cardiac failure, acute hypertension or stroke. 
Care should therefore be taken not to aim for baseline haemoglobin 
levels during transfusion.
Education of parents to palpate for splenomegaly from infancy/
early childhood allows for early recognition and prompt intervention 
of this emergency situation.[7]
2.3 Aplastic crisis
In the context of SCD, as in other haemolytic states, aplastic crisis 
refers to pure red cell aplasia, where there is selective erythroid 
hypoplasia or aplasia with resultant reticulocytopenia. The most 
common cause is infection with parvovirus type B19, which infects 
early erythroid precursors through the glycophorin receptor. In 
normal individuals this infection rarely causes anaemia, but in 
haemolytic states where there is maximal erythropoietic activity, 
destruction of erythroid precursors leads to rapid development of 
severe anaemia. Blood transfusion is the mainstay of management. 
Intravenous gamma globulin and/or corticosteroids may be 
indicated for the treatment of parvovirus B19 infection.
2.4 Haemolytic crisis
Haemolytic crisis may be caused by an acute VOC, malarial 
infection or oxidant drug exposure in individuals with concomitant 
glucose-6-phosphate dehydrogenase (G6PD) deficiency. 
Haemolytic crisis may be distinguished from aplastic crisis by 
the finding of a reticulocytosis as opposed to a reticulocytopenia. 
Rarely, a hyperhaemolysis syndrome may be triggered by a red cell 
transfusion. Here the haemoglobin concentration drops to below 
pretransfusion levels as a result of destruction of allogeneic as 
well as autologous red cells without any evidence of an antibody-
mediated transfusion reaction. The mechanism of hyperhaemolysis 
is not known, but it is thought to result from hyperactive 
macrophage activity. Corticosteroids (first line) and intravenous 
immunoglobulin are the mainstays of treatment. Since red cell 
transfusion during an episode of hyperhaemolysis can accelerate 
the haemolytic process, additional transfusions should be limited 
to situations of life-threatening anaemia.
3. Complications and organ damage
3.1 Infection
Increased susceptibility to infection in SCD patients may be due 
to a number of predisposing factors, including functional asplenia 
(hyposplenism), impaired complement activity, zinc deficiency, iron 
overload and the presence of necrotic tissue. The spleen is an early 
casualty of organ damage from repeated infarctive episodes, which 
reduce it to a nubbin of fibrous tissue. Functional asplenia in 
particular increases the propensity to infections with encapsulated 
bacteria and malaria, which may be life-threatening. Key to a 
successful outcome is early recognition and prompt therapeutic 
intervention.
Osteomyelitis is often a result of vaso-occlusion, ischaemia and 
infarction, with consequent bone necrosis and secondary infection. 
In addition, bacteraemia may lead to osteomyelitis or septic 
arthritis.
Management of osteomyelitis entails:
• Supportive care including bed rest, splinting of the affected limb,
analgesia, hydration and oxygenation
• Surgical drainage where necessary
• Administration of intravenous antibiotics for 2 - 6 weeks.
Appropriate antibiotics include the cephalosporins such as
ceftriaxone and the quinolones in Salmonella osteomyelitis, and
cloxacillin where Staphylococcus aureus is suspected.
See below for preventive measures against infection.
3.2 Cardiovascular complications
Cardiovascular complications have become more evident with 
increasing longevity in patients with SCD and include pulmonary 
hypertension, left and right ventricular dysfunction, myocardial 
infarction, arrhythmias and sudden death.[8]
3.2.1 Pulmonary hypertension (PHT)[9]
PHT occurs in 5 - 30% of patients with SCD and is a risk factor 
for sudden cardiac death. Although the precise mechanism has 
not been defined, chronic haemolytic anaemia and release of free 
haemoglobin, which inactivates nitric oxide, may have an important 
role in the causation of pulmonary vasculopathy. Proliferation of 
smooth-muscle cells with resultant vascular obliteration leads to a 
pathological picture almost identical to that seen in idiopathic PHT. 
Other factors that contribute to the development of PHT in this 
population include functional asplenia, thromboembolism, lung 
fibrosis, hypoxia and left ventricular dysfunction.
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Echocardiography is the most useful screening test when PHT is 
suspected on clinical grounds, but it should be emphasised that 
definitive confirmation requires invasive right-heart catheterisation. 
The echocardiographic definition of PHT is a pulmonary artery 
systolic pressure >40 mmHg, while the haemodynamic definition of 
PHT is a mean pulmonary artery pressure (MPAP) >25 mmHg at rest, 
measured at cardiac catheterisation. A raised tricuspid regurgitant 
velocity (TRV) (>2.5 m/s) on Doppler echocardiography correlates 
well with an increased MPAP, and is more suitable for regular screening 
of patients owing to the non-invasive nature of the test. However, a 
diagnosis of PHT based on an elevated TRV needs to be confirmed 
with cardiac catheterisation, as not all patients with a raised TRV have 
PHT. Several studies have confirmed that a TRV >2.5 m/s is associated 
with a 9 - 16 times increased risk of death. These patients should be 
referred to a cardiologist for further management and follow-up.
Therapeutic interventions include:
• Prostacyclin analogues (e.g. epoprostenol, iloprost)
• Phosphodiesterase type 5 inhibitors (e.g. sildenafil)
• Endothelin receptor antagonists (e.g. bosentan).
3.2.2 Left ventricular dysfunction (LVD)
LVD is not infrequent and is largely related to the duration and 
severity of anaemia. Compensatory left ventricular hypertrophy 
and dilatation are accompanied by both systolic and diastolic 
dysfunction and consequent heart failure. Other factors contributing 
to the heart failure phenotype include systemic hypertension, chronic 
inflammation, and possibly direct myocardial damage as a result of 
microvasculopathy.
The treatment of LVD and heart failure should follow standard 
guidelines and include diuretics, digitalis, beta-blockers and 
angiotensin-converting enzyme (ACE) inhibitors.
3.2.3 Myocardial infarction (MI)
MI has been documented in SCD, but the mechanisms are unclear 
because coronary angiography rarely reveals obstructive coronary 
disease. Other mechanisms that have been postulated include 
microvascular obstruction and endothelial dysfunction. The role of 
standard therapies for MI such as antiplatelets and thrombolytics 
remain unclear, although most patients improve with standard 
management of the sickle cell crisis.
3.3 Renal complications
Patients may present with symptoms early on in life and may manifest 
with the following complications:
3.3.1 Hyposthenuria
Hyposthenuria refers to an inability to concentrate urine maximally 
and is a common renal abnormality in SCD. Hyposthenuria typically 
manifests as enuresis in early childhood (in rare cases it may continue 
into the teenage years) and may cause nocturia in adults. Maintaining 
good hydration is important, as these patients are more susceptible to 
dehydration than normal individuals.
3.3.2 Haematuria
Haematuria may occur in homozygous SCD (HbSS) as well as hetero-
zygous SCD (HbAS) and is caused by renal papillary necrosis resulting 
from ischaemic damage to the renal medulla. Treatment involves bed 
rest, maintenance of a high urinary flow, and blood transfusion if blood 
loss is significant. In the event of excessive or life-threatening bleeds, 
local resection of the bleeding segment in the kidney is preferable. It is, 
however, important to exclude other causes of haematuria.
3.3.3 Proteinuria
Screening for proteinuria should be performed annually with a 
urine dipstick. If positive, a 24-hour protein estimation or urine 
albumin/creatinine ratio is indicated. For patients with albuminuria, 
ACE inhibitors or angiotensin-II receptor antagonists are usually 
beneficial.
Renal function should be monitored annually (urine for 
microalbuminuria, blood urea, electrolyte and creatinine levels). 
Serum creatinine levels are generally low in SCD, so a rise in the 
creatinine level to within the normal range often signals the onset 
of renal impairment. Long-term use of NSAIDs should be avoided, 
particularly in patients with evidence of renal impairment. Renal 
transplantation may be considered in patients with end-stage renal 
failure.
Patients with renal dysfunction should be assessed and followed up 
by a renal physician.
3.4 Avascular necrosis (AVN)
Osteonecrosis or AVN occurs when repetitive vaso-occlusion results 
in the infarction of articular surfaces and juxta-articular bone, e.g. 
the head of a long bone. The most common sites are heads of femoral 
bones and humeri, followed by the knee (tibial condyles) and small 
joints of the hands and feet. The femoral head is highly vulnerable to 
ischaemic damage because its blood supply depends solely on an end-
artery. Multiple joints are often affected. Pain due to AVN is most 
noticeable during weight bearing and there may also be functional 
limitation of the joint. Early disease is best detected by MRI (signal 
intensity changes, irregular bony and articular outline). Plain X-rays 
detect only more advanced disease (flattening of the head, coarsening 
of the bone architecture, cystic areas, sclerosis). Isotope bone scans 
may detect osteonecrosis as focal areas of increased activity. Without 
treatment it is expected that most affected femoral heads will collapse 
within 5 years of diagnosis. Treatment options include a more 
conservative approach in children, with analgesia (paracetamol, 
mild opiates, NSAIDs), physiotherapy and protected weight bearing 
(avoidance of weight bearing) for approximately 3 - 6 months. 
Secondary degenerative arthritis can compound the osteonecrosis 
in adults and a conservative approach is less effective. Analgesia, 
core decompression and realignment osteotomy with aggressive 
physiotherapy are used in early disease, while joint replacement 
is reserved for patients with severe manifestations of advanced 
disease. There is a high rate of perioperative complications, which 
include blood loss, acute chest syndrome, infection and failure of the 
prosthesis.
3.5 Leg ulceration
Leg ulceration is a frequent complication of SCD in adults and most 
commonly occurs over the shins and malleoli. Leg ulcers should be 
treated promptly to minimise progression to a chronic state.
Investigation and management of leg ulcers include the following:
• Swab for culture if infected, and treat as per sensitivity results.
Osteomyelitis should be excluded if there is fever and bone
tenderness. An MRI scan may be indicated to establish a diagnosis 
of osteomyelitis.
• Topical emollients and wound dressings to promote moist wound
healing. Graduated compression bandages will reduce venous
hypertension. Zinc supplementation may be of benefit in terms of
wound healing, as the patients tend to be in negative zinc balance.
Topical antibiotics should be avoided to prevent sensitisation.
• Arterial insufficiency should be excluded. If discovered, the patient 
must be referred to a vascular surgeon.
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• For those who fail to respond to the above measures, the attending 
doctor should consider:
• Regular blood transfusions until wound healing occurs (a costly 
option)
• Wound dressings with Thrombostim, a product developed and
manufactured by the South African National Blood Service
(SANBS). Thrombostim is a dual-component treatment system
containing lyophilised platelet-rich plasma, which is rich
in platelet-derived growth factor (PDGF), and lyophilised
thrombin. PDGF is essential for the wound healing process.
The surgical team should be involved in the management of patients 
with chronic leg ulcers.
3.6 Gallstones
Formation of gallstones is a common complication of SCD, and if 
the patient is symptomatic, cholecystectomy should be performed. A 
laparoscopic procedure is preferred.
3.7 Ocular complications
In the early stages ocular complications are usually clinically silent. 
Anterior- and posterior-segment changes of the eye can occur. 
Retinal changes are broadly categorised as follows:
3.7.1 Non-proliferative retinopathy
Non-proliferative retinopathy includes ‘salmon patches’ and ‘black 
sunbursts’. These changes occur as a result of peripheral retinal 
haemorrhages due to arteriolar occlusion and rupture of the blood 
vessel. This does not normally lead to visual loss.
3.7.2 Proliferative retinopathy
Proliferative retinopathy is predominantly encountered in young adults 
with SCD (including HbSS and HbSC disease). Neovascularisation 
occurs in response to microvascular occlusion and ischaemia. This 
may lead to complications such as vitreous haemorrhage and retinal 
detachment, which is a cause of sudden loss of vision.
Pan-retinal photocoagulation laser therapy is effective in preventing 
vision-threatening complications such as vitreous haemorrhage and 
retinal detachments. Antivascular endothelial growth factor (anti-
VEGF) agents such as bevacizumab have also been used in the 
treatment of proliferative retinopathy.
Annual ophthalmic assessment is recommended.
3.8 Chronic pain
A multidisciplinary team is required for the optimal management of 
chronic pain. The cause of the pain should be determined. Where 
circumstances permit, home management should be encouraged.
• Pharmacological management should include medium- to long-acting 
opioids, as the use of frequent short-acting opioids is less effective.
NSAIDs should be used judiciously with 3-monthly monitoring of
renal function. For breakthrough pain, alternative analgesia such as
fentanyl or oxycodone may be used, where available.
• Non-pharmacological measures should be considered where
necessary, such as physiotherapy, acupuncture, etc.
• Surgical options may be exercised where indicated, e.g.
decompression or total hip replacement for avascular necrosis
of the hip and cholecystectomy for gallstones. Perioperative
thromboprophylaxis is imperative.
• Chronic headache is common in SCD, and any exacerbation or
change in the nature of the pain warrants neurological assessment
(to exclude potentially life-threatening events such as intracranial
haemorrhage or venous sinus thrombosis).
4. Preventive measures
4.1 Patient education
Patients as well as caring family members need to be informed 
about the disease process, with particular attention being paid to the 
following:
• Precipitating factors
• Home management. The aim is to recognise symptoms or signs
that require hospital admission, and at the same time abort the
various forms of acute crises. A supply of simple analgesics should
be made available for managing milder forms of sickle crises.
Parents should be taught the art of palpating for the spleen in order 
to pre-empt a splenic sequestration crisis.
• Genetic counselling.
4.2 Infection control
Globally, infection is the leading cause of death in developing 
countries. The factors responsible for increased susceptibility to 
infections in SCD have been mentioned previously. In particular, 
hyposplenism renders patients more susceptible to the detrimental 
effects of encapsulated organisms and malaria. In addition, infection 
is a common precipitant of an acute crisis, and prompt treatment with 
appropriate antibiotics is therefore essential.
4.2.1 Antibiotics
There is debate on the prophylactic use of oral antibiotics in all patients 
with SCD. However, penicillin VK 125 mg twice daily orally for children 
under 3 years of age and 250 mg bid for children older than 3 years of 
age is recommended, and continued until adolescence. Erythromycin 
is recommended for patients who are allergic to penicillin.
4.2.2 Immunisation
• Pneumococcal vaccine. Adults and children >2 years of age should 
receive the unconjugated vaccine (Pneumovax 23®). Conjugated
vaccine (Prevenar 13®) is provided to children under the age of 2
years as part of the national immunisation schedule. Children who 
have missed the conjugated vaccine should have two doses of the
conjugated vaccine followed by a dose of the unconjugated vaccine, 
at 6 - 8-week intervals.
• Conjugated meningococcal C vaccine. If not given as part of the
childhood immunisation programme, a single dose should be given.
• Haemophilus influenzae type B vaccine. If not given as part of
the childhood immunisation programme, a single dose should be
given.
• Annual influenza vaccination is recommended.
4.3 Nutritional supplements
• Folic acid becomes depleted owing to its high turnover as well as
loss from chronic haemolysis. A dose of 1 - 2 mg daily is adequate
to supplement the increased requirements of folate.
• Zinc is a constituent of the metalloenzyme carbonic anhydrase,
which is lost in intravascular haemolytic states. Zinc should
be supplemented in individuals displaying symptoms of zinc
deficiency, viz. malaise, listlessness and fatigue or repeated
infections.
• Repeated transfusions can lead to iron overload. However,
individuals who are not regularly transfused can develop a negative 
iron balance, necessitating supplementation.
4.4 Family screening
Family members and prospective partners should be screened. 
Cultural and societal sensitivities often pose a challenge to effective 
screening programmes, largely owing to stigma associated with the 
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disease. An aggressive education drive is necessary to overcome 
such barriers. The most convenient method of screening for SCD is 
high-performance liquid chromatography (HPLC), since it is reliable, 
automated and allows for high throughput. Hb electrophoresis may 
be used as a confirmatory test. The slide sickle and solubility tests, 
although still used in some under-resourced centres, are far from 
ideal because they may not distinguish HbAS from HbSS and also 
cannot detect compound heterozygous states.
4.5 Antisickling agents
There are various antisickling agents, such as hydroxyurea (HU), 
statins, clotrimazole and butyrate. Of the available agents, HU has 
proven to be the most effective. HU is a cytotoxic agent that acts by 
inhibiting the enzyme ribonucleotide reductase. The mechanisms of 
action of hydroxyurea include:
• Increase in HbF concentration. HbF does not participate in
formation or elongation of the sickle tactoids and as such retards
the sickling process.
• Increase in the mean cell volume, which prolongs the delay time
(time taken for a red cell to sickle).
• Reduction of cell counts and adhesion molecules, thereby
improving the rheology and flow of blood.
HU is indicated in all adult patients with SCD. Use in children 
has been less definitive, however, primarily owing to concerns 
regarding fertility and potential mutagenicity. There is no clear-cut 
evidence that long-term use of HU (when used for the treatment 
of benign disorders) leads to an increased risk of secondary 
malignancies. Although infertility is not a recognised complication, 
reduced sperm counts and a decrease in sperm motility have 
been demonstrated, which appear to improve or reverse after 
discontinuation of HU. On the contrary, numerous studies have 
demonstrated the benefits of HU, viz. a decreased number of acute 
crises, decreased transfusion requirements and organ preservation 
in children. Institution of HU therapy is therefore recommended 
in children with SCD >2 years of age.[7] The dosage scheme of HU 
is as follows: Start at 10 - 15 mg/kg/d and increase to a maximum 
of 30 mg/kg/d. The dose should be titrated against the neutrophil 
count and increased by 5 mg/kg increments at 3-monthly intervals. 
The dose should be decreased if the neutrophil count drops below 
1.5 × 109/L, and stopped if it drops below 1 × 109/L or when 
conception is planned.
4.6 Gout prevention
Elevation of uric acid levels are closely linked with the degree 
of haemolysis. There may also be a contribution from the use of 
hydroxyurea or renal dysfunction. A uric acid-lowering agent such as 
allopurinol is recommended where the uric acid levels are elevated.
4.7 Outpatient visits
Regular outpatient visits are essential for monitoring and early 
detection of organ dysfunction. (See Appendix 3 for a recommended 
schedule of outpatient visits.)
Disclaimer. The advice and information in these guidelines is largely 
evidence based and believed to be true and accurate at the time of going 
to press. The authors or publishers therefore cannot accept any legal 
responsibility for these recommendations. It should also be noted that, 
for reasons of conscience, not all the authors agree on termination of 
pregnancy beyond situations where the life of the pregnant woman is 
endangered.
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Appendix 1. Pregnancy and 
contraception in SCD
Pregnancy is a major decision for a woman with SCD, since it is 
associated with a number of maternal and fetal complications. 
Maternal complications include VOC (30 - 50%), infections (28%), 
anaemia (34%), pre-eclamptic toxaemia (PET)/eclampsia (9%), 
preterm labour (24%), etc. Fetal complications include miscarriage, 
abruptio placentae, placenta praevia, preterm delivery (24%), low 
birth weight (20%), fetal distress (14%), stillbirths (0.9%), etc.
Improvements in obstetric and perinatal care have resulted in a 
decrease in maternal and perinatal mortality (from 11.5% in the 
1970s to <2%). The philosophy of avoidance of pregnancy in the past 
has now shifted to one of support and comprehensive stepwise care, 
for which a multidisciplinary team including the haematologist and 
obstetrician is required. This is summarised below.
Management of SCD in pregnancy[10,11]
1. Screening and counselling of young women at risk
• Education
• Issues surrounding fertility, contraception and pregnancy
• Choice and screening of spouse/partner
• Discussion of potential maternal and fetal complications.
• Planning of the pregnancy prior to conception – discuss discon-
tinuation of HU prior to conception, pneumococcal vaccin ation,
and need for continuation or termination of pregnancy (TOP).
2. Antenatal diagnosis. This is not without risk of complications and 
should be undertaken if TOP is a realistic option. Techniques include 
chorionic villous sampling at 9 - 13 weeks, amniocentesis at 15 - 16 
weeks and fetal blood sampling at 18 - 20 weeks.
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3. Antepartum management
• Early booking is advised, ideally by
12 - 14 weeks. Recommended follow-
up frequency: monthly until 28 weeks,
fortnightly until 34 weeks and weekly after 
34 weeks.
• Close monitoring of mother and fetus is
needed for early detection of recognised
complications. Perform growth scans/
ultrasound monthly until 34 weeks, then
fortnightly until delivery. Weekly non-
stress testing from 32 weeks’ gestation is
recommended.
• Folic acid 5 mg daily, and iron supple-
mentation if indicated.
• Blood transfusion – prophylactic trans-
fusion for uncomplicated pregnancy
is not recommended. Indications for
blood transfusion include: anaemia
associated with cardiorespiratory
disease, acute chest syndrome, refractory 
PET, preparation for caesarean section
(CS) and other medical or obstetric
indications.
4. Labour and delivery
• Timing and route of delivery should be
based on obstetric indications as in non-
SCD cases.
• During labour ensure good pain relief,
adequate hydration, oxygen, and fetal and
maternal monitoring.
• Avoid long and exhausting labour and
delivery.
• For CS, optimise surgical and anaesthetic
risks (e.g. transfusion, hydration, oxygen-
ation, temperature control, etc.). Beware
of acute chest syndrome post-surgery
(peak 48 hours post surgery).
• Where opiates are used, be aware of the
sedative and depressive effects. If they
are used prior to or during labour and
delivery, a neonatologist should be alerted, 
and be present at delivery in case of fetal
sedation.
5. After delivery
• Owing to the increased risk of
thromboembolic disease, aim for early
ambulation and use of stockings, with
thromboprophylaxis in high-risk indivi-
duals.
• During breastfeeding, avoid HU and
ensure good hydration.
• It is important to offer family planning
advice with the various options on
contraception, viz. oral contraceptive pill
(including combined and progesterone-
only pill), depot medroxyprogesterone
acetate, barrier methods and copper
intrauterine contraceptive devices, which
are all acceptable in SCD.
6. Neonate
• Establish early diagnosis – an umbilical
cord blood sample may be used for con-
venience.
• In the case of a child born with SCD,
institute a comprehensive care programme 
where both the paedia trician and the
haematologist are invol ved in manage-
ment.
Appendix 2. Blood 
transfusion and iron 
overload in SCD[12]
Blood transfusion remains an important 
component of the management of patients 
with SCD. The rationale behind transfusion 
is to improve microvascular perfusion and 
oxygen-carrying capacity and decrease the 
proportion of sickle cells in the circulation.
Indications for transfusion are set out in 
Table 2.
Transfusion for anaemia is generally 
indicated in symptomatic patients with a 
>20% drop in haemoglobin or a decrease in 
oxygen saturation. The goal of transfusion 
should be to reduce the level of HbS to 
<30% and in order to prevent the problems 
of hyperviscosity, achieve a post-transfusion 
haemoglobin concentration not exceeding 
9 - 10 g/dL.
The role of transfusion in stroke is 
discussed under ‘Acute VOC’ (2.1.2).
Controversial indications for transfusion 
include priapism, pregnancy and patients 
with chronic leg ulcers (cf. respective 
sections).
Simple v. exchange transfusion. The 
deci sion with regard to each of the 
modalities of transfusion will depend on 
the indication, clinical circumstances and 
available resources. Exchange transfusion 
has the added advantage of reducing HbS 
effectively without the risk of increasing 
viscosity or causing volume overload. 
Simple transfusion has the advantage 
of ease of administration, as well as 
accessibility outside major medical centres. 
The disadvantages include the potential to 
increase viscosity, as well as the risk of iron 
and volume overload.
The optimal management strategy 
should also include measures to limit 
the complications associated with blood 
transfusion, the most important being 
alloimmunisation and iron overload. 
Alloimmunisation is a commonly encoun-
tered complication in patients with 
SCD, and extended phenotyping has 
been shown to reduce the incidence of 
this complication. Testing for at least D, 
C/c, E/e and K antigens is recommended 
before commencing transfusions, and 
phenotypically matched, leucodepleted 
blood should be administered.
Patients receiving regular transfusions 
should have regular monitoring of their 
iron status, and chelation therapy should 
be commenced appropriately. The iron 
chelators available are deferoxamine (given 
parenterally), deferiprone and deferasirox 
(given orally). Oral iron chelators are 
preferred, as they improve patient compli-
ance. Deferiprone should be avoided in 
patients with aplastic crisis or neutropenia 
because it is known to cause agranulocytosis 
in some patients.
Appendix 3. Outpatient 
follow-up and transition 
of care in SCD
Outpatient follow-up
In the initial stages, patients should be seen 
at the haematology outpatient clinic on a 
monthly basis. Intervals between visits may 
be increased to 3 months once the patient is 
stable and therapy is optimised.
Investigations conducted at outpatient 
level for monitoring purposes are listed in 
Table 3.
Transition of care[13]
Transfer of care from a paediatric to an adult 
team is a major life-changing event for the 
young patient with HbSS.
With advances in medical care, >90% of 
patients with SCD now reach adulthood, 
with the majority living into their forties. 
Table 2. Indications for blood transfusion in SCD
Acute Chronic 
Symptomatic anaemia
Splenic/hepatic sequestration crisis
Acute chest syndrome
Acute neurological syndromes
Perioperative (major surgery)
Acute multiorgan failure
Sepsis
Primary or secondary stroke prevention
Pulmonary hypertension
Recurrent sequestration crisis/chest syndrome
Anaemia associated with chronic renal failure
Congestive cardiac failure
SCD = sickle cell disease.
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Longer survival has increased the need for successful transition of 
care from paediatric to adult services.
The handover from paediatric to adult services should be planned 
and managed as a process and should begin after the age of 12 
years. The optimal time for transition should be individualised and 
requires assessment of the level of readiness as well as patient and 
parent education about their illness and the transition process. The 
anxiety of patients during a transfer process centres around transfer 
of their history, the adult service’s attitude to issues pertaining to pain 
management, and practical issues such as appointments, etc.
Methods to facilitate the process include printed literature, 
meet ing with a support group or someone who has successfully 
transitioned, visiting the adult service before the first appointment, 
and the establishment of special combined clinics.
Appendix 4. Haematopoietic SCT for 
SCD[14,15]
Allogeneic SCT offers the only chance of cure in SCD. Gene therapy 
is still in the development phase and is currently not a realistic 
option. The indications for transplantation in SCD remain poorly 
defined owing to the variable phenotypic expression of the disease 
with age. The general experience in transplantation for this disease 
is also less than in thalassaemia. As a rule, in the absence of severe 
organ dysfunction, this treatment option should be considered in all 
moderately or severely symptomatic children if an HLA-identical 
donor is available. Results are better if transplantation is performed 
at an earlier age, particularly before irreversible sickle vasculopathy 
is established.
While the outcome of transplantation for SCD has been favourable, 
the main limiting factors for its wider use are lack of HLA-
compatible donors, infrastructure and expertise, and cost. Outcomes 
depend on certain risk factors associated with the treatment of the 
haemoglobinopathy, such as irregular iron chelation therapy, which 
significantly increases transplant-related mortality. In addition, 
transplantation for SCD may have unique complications such as 
cerebrovascular occlusive/haemorrhagic episodes with stroke, 
convulsions requiring prophylaxis with anticonvulsive therapy, 
meticulous control of electrolytes, and maintaining higher than 
baseline blood haemoglobin levels and platelet counts throughout 
the procedure.
For the success of this type of therapy, two barriers must 
be overcome, viz. graft rejection and graft-versus-host disease 
(GVHD). For effective engraftment myeloablative conditioning 
is preferred, particularly in view of the highly cellular marrow 
as a consequence of chronic haemolysis and the brisk immune 
response resulting from exposure to allogeneic antigens during 
blood transfusions. The specifics of myeloablation are beyond the 
scope of this review.
The probabilities of overall survival, sickle cell-free survival and 
transplant-related mortality are 92%, 86% and 5%, respectively. 
Despite the appropriate use of immunosuppressive agents, 
approximately one-third of patients will develop clinically relevant 
scores of GVHD, necessitating further therapy with corticosteroids 
and immunosuppressive agents. Adult patients usually have more 
advanced disease, and therefore greater comorbidities and higher 
treatment-related mortality.
A proportion of patients may have re-emergence of their own 
haematopoiesis with persistent and stable chimerism, which is 
generally associated with an asymptomatic state. In contrast to 
transplantation for malignancies, mixed chimerism in haemo-
globinopathies therefore does not necessarily mean treatment 
failure. Allogeneic SCT is an effective treatment option, and 
currently the only proven curative therapy for patients with 
SCD. By removing the sickle cell phenotype, the vasculopathy is 
reversed and patients are likely to have a normal quality of life. 
Challenges remain the broader availability of this procedure with 
the use of alternative donors, as well as enhancing engraftment and 
preventing GVHD. 
Table 3. Guide to outpatient monitoring of SCD
Baseline Monthly 6-monthly Annual Biennial
FBC + differential × ×
U + E × ×
LFTs × ×
Urine for microalbumin × ×
Chest X-ray × ×
TRV (>10 yr) × ×
Lung function tests (>10 yr) × ×
TCD (paediatric population) × ×
Ocular assessment × × Adults × Older children with 
HbSC
Serum ferritin (if regularly transfused) ×
SCD = sickle cell disease; FBC = full blood count; U + E = urea and electrolytes; LFTs = liver function tests; TRV = tricuspid regurgitant velocity; TCD = transcranial Doppler.
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